Junges Vilma Maria, Cavalheiro Jarbas Marinho, Fam Eliana Franzoi, Closs Vera Elizabeth, Moraes João Feliz, Gottlieb Maria Gabriela
Programa de Pós-Graduação em Gerontologia Biomédica do Instituto de Geriatria e Gerontologia da Pontifícia Universidade Católica do Rio Grande do Sul (IGG-PUCRS), Porto Alegre, RS, Brazil.
Centro Integrado de Tratamento da Obesidade (CINTRO), Porto Alegre, RS, Brazil.
Arq Gastroenterol. 2017 Apr-Jun;54(2):139-144. doi: 10.1590/S0004-2803.201700000-11. Epub 2017 Mar 16.
The prevalence of obesity and metabolic syndrome is increasing worldwide and both behavior modification and drug therapy have low adherence. Gastric bypass has shown effective results in both reducing weight and improving comorbidities.
To evaluate the impact of Roux-en-Y Gastric Bypass Surgery (RYGB) on both metabolic syndrome components and the use of associated drugs in obese patients.
Historical cohort of patients subjected to Roux-en-Y Gastric Bypass Surgery (RYGB) between January 2007 and March 2014 in a private clinic. The sample consisted of 273 obese class II and III individuals, 86.4% of whom were female, with age ≥20 years, followed up for 2 months after surgery. Sociodemographic, anthropometric, biochemical, clinical, and drug-use data were collected from patients' medical records.
Significant differences were found in weight, body mass index and waist circumference, after 60 postoperative days. Components for metabolic syndrome diagnosis (hypertension P=0.001; hyperglycemia P<0.001; hypertriglyceridemia P=0.006) were reduced after 60 days of postoperative, with the exception HDL-c (P=0.083). There was a significant reduction in the use of antihypertensive (P<0.001), hypoglycemic (P=0.013), lipid lowering (P<0.001), and antiobesity (P=0.010) drugs and increased use of gastroprotective drugs, vitamins, and minerals (P<0.001) after 60 postoperative days.
Patients subjected to Roux-en-Y Gastric Bypass Surgery exhibited both weight loss and significant improvement not only in metabolic syndrome components (except for HDL-c) but in the use of drugs associated with obesity and metabolic syndrome.
肥胖和代谢综合征在全球范围内的患病率正在上升，行为改变和药物治疗的依从性都很低。胃旁路手术在减轻体重和改善合并症方面均显示出有效结果。
评估Roux-en-Y胃旁路手术（RYGB）对肥胖患者代谢综合征组分及相关药物使用的影响。
对2007年1月至2014年3月在一家私立诊所接受Roux-en-Y胃旁路手术（RYGB）的患者进行历史性队列研究。样本包括273例II级和III级肥胖个体，其中86.4%为女性，年龄≥20岁，术后随访2个月。从患者病历中收集社会人口学、人体测量学、生化、临床和药物使用数据。
术后60天，体重、体重指数和腰围有显著差异。术后60天，代谢综合征诊断组分（高血压P=0.001；高血糖P<0.001；高甘油三酯血症P=0.006）有所降低，但高密度脂蛋白胆固醇除外（P=0.083）。术后60天，抗高血压药物（P<0.001）、降糖药物（P=0.013）、降脂药物（P<0.001）和抗肥胖药物（P=0.010）的使用显著减少，胃保护药物、维生素和矿物质的使用增加（P<0.001）。
接受Roux-en-Y胃旁路手术的患者不仅在代谢综合征组分（高密度脂蛋白胆固醇除外）方面，而且在与肥胖和代谢综合征相关的药物使用方面均表现出体重减轻和显著改善。
